Press Releases Cereno Scientific AB

Equities

CRNO B

SE0008241558

Delayed Nasdaq Stockholm Other stock markets 07:34:14 23/05/2024 pm IST			5-day change	1st Jan Change
4.006 ^SEK	+7.46%		+12.09%	-12.44%

08:30am	Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)	12:01pm	AQ
Cereno Scientific presents at ABGSC Investor Days, May 23	17/05	AQ
Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress	15/05	AQ
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025	02/05	AQ
Report from Annual General Meeting 2024 of Cereno Scientific AB	16/04	AQ
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family	11/04	AQ
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014	10/04	AQ
Cereno Scientific announces extended patent protection in Europe for CS585 program	09/04	AQ
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific	03/04	AQ
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH	28/03	AQ
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific	27/03	AQ
Cereno Scientific publishes Annual Report for 2023	26/03	AQ
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community	25/03	AQ
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1	22/03	AQ
Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov	21/03	AQ
Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million	21/03	AQ
Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1	19/03	AQ
Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific	14/03	AQ
Cereno Scientific's nomination committee proposes Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors	14/03	AQ
The Nomination Committee's proposed resolution to the Annual General Meeting on 16 April 2024	14/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cereno Scientific AB

Equities

CRNO B

SE0008241558

Press Releases

Filters